Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • Equity, Diversity, and Inclusion
    • Innovations in Care Delivery
    • Without Borders
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • Equity, Diversity, and Inclusion
    • Innovations in Care Delivery
    • Without Borders
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Articles
  • Issues

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Genetics
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues

Share

August 2018; 4 (4) Clinical/Scientific NotesOpen Access

GLRA1 mutation and long-term follow-up of the first hyperekplexia family

Martin Paucar, Josefine Waldthaler, Per Svenningsson
First published August 7, 2018, DOI: https://doi.org/10.1212/NXG.0000000000000259
Martin Paucar
From the Section of Neurology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josefine Waldthaler
From the Section of Neurology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Per Svenningsson
From the Section of Neurology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
GLRA1 mutation and long-term follow-up of the first hyperekplexia family
Martin Paucar, Josefine Waldthaler, Per Svenningsson
Neurol Genet Aug 2018, 4 (4) e259; DOI: 10.1212/NXG.0000000000000259

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
218

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Hyperekplexia (HPX) is a rare familial disorder characterized by an exaggerated startle reflex and stiffness at birth. In 1958, Boris P. Silfverskiöld published a report on a Swedish family affected by “emotionally precipitated drop seizures.”1 This first description of HPX became seminal, but it would take 35 years before mutations in the glycine receptor subunit alpha-1 (GLRA1) gene were discovered as the cause of this disease.2 Subsequently, SLC6A5 and GLRB mutations were discovered as causes of HPX.3 Here, we present a 60-year follow-up of the Silfverskiöld family found to harbor the R271Q mutation in the GLRA1 gene. Some affected patients in this family display unreported features for HPX.

Methods

This report was made within the frame of a study approved by the local ethics committee (Etikprövningsnämnden 2016/1661-31). The family consisted of 4 affected patients (figure). Phenotype details are provided in the original article and summarized in table e-1 (links.lww.com/NXG/A64). Briefly, 3 patients had early-onset violent and injurious falls triggered by unexpected stimuli (II-1, II-2, and III-1) causing a skull fracture in 2 (II-1 and II-2). Three patients had hypnagogic myoclonus and a good response to phenobarbital. At times, symptoms receded spontaneously in patient II-1. Reported onset in I-1 (J.E.) was at age 40 years; he had startle with falls once or twice per year. Siblings II-1 (A.W.) and II-2 (B.E.) lost consciousness sometimes after startle-related falls.1 Patient II-1 was diagnosed with late-onset dementia and died at age 87 years; patient II-2 was found drowned in a bathtub at age 76 years. Patient III-1 was aged 10 years at the time of the publication; at present, she is a 66-year-old retired school teacher. She was diagnosed with stiff baby syndrome. Patient III-1 had symptoms until age 13 years. At that point, symptoms receded spontaneously until age 27 years. When her symptoms reappeared, beneficial treatment with clonazepam was started and continued since then. Patient IV-1, born in 1976, presented with insidious clumsiness starting in childhood and later startle reactions. She underwent surgery for umbilical hernia at age 1 year. Stiffness became gradually persistent between startle reactions during adolescence; treatment with clonazepam was started at age 22 years. She has also been on continuous antidepressant treatment; Gabapentin was added later because of diffuse pain. She works part time as a preschool teacher. At age 32 years, she developed anxiety, weight loss, and gait difficulties. On examination, an exaggerated head-retraction reflex, hesitant gait, tremulous jerks in all extremities, and tremor of variable frequency were evident; the latter indicates a functional overlay. EMG displayed 80 ms polymorph bursts with a constant frequency of 7 Hz; there was no evidence of neuropathy; MRI of her brain was normal. The heterozygous mutation c.896G>A (R271Q) in GLRA1 was found in patients III-1 and IV-1.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure Updated pedigree of the Silfverskiöld hyperekplexia family described originally in 1958

Phenotype details on patients III-1 and IV-1 are provided in the text, both patients harbor the recurrent R271Q mutation in GLRA1.

Discussion

The R271Q mutation in GLRA1 found in the Silfverskiöld family is consistent with a phenotype previously described in association with GLAR1 mutations. HPX phenotype was variable in this family, but there are some novel features. For instance, the waxing and waning course (patient II-1) and adult onset (I-1) have not been described in other GLRA1 mutations. In addition, another patient (III-1) had a spontaneous remission for 14 years. Anxiety is unreported in HPX; in the index case, this feature could be related to fears of fall. Also unusual is the absence of perinatal stiffness, considered as one of the diagnostic criteria for HPX, and the functional overlay in the index case. Incongruence and variable frequency of tremor in the index case are compatible with a psychogenic movement disorder. Reports on the occurrence of psychogenic movement disorders in the context of a positive family history of hyperkinesias are scarce.4 HPX is responsive to clonazepam, and the Vigevano maneuver is effective during the neonatal period.3 HPX associated with GLRA1 mutations is in most cases an autosomal recessive disease.2,3 Hypnagogic myoclonus and umbilical hernia have been described in association with GLRA1 mutations. We did not find any of the other features associated with HPX such as apnea, seizures, developmental delay, learning disabilities, or sudden death.3 These features are more likely to occur in patients with biallelic GLRA1 mutations or in HPX associated with mutations in SLC6A5 and GLRB.3 Less often are heterozygous GLAR1 mutations associated with mild developmental delay.3 R271Q is the most common dominant GLRA1 mutation identified in families of different ethnicities; a founder effect among Caucasian patients has been proposed.3,5 R271Q is located in the second membrane-spanning domain of the receptor, which is expressed on the cell surface but displays reduced current and channel opening.6

HPX occurs also as part of severe neurodevelopmental syndromes associated with mutations in ARHGEF9 and GPHN, the latter is a lethal condition, which illustrates the importance of etiologic diagnosis. A variety of animal models and in vitro studies have provided valuable knowledge on HPX associated with GLRA1 mutations,3,6,7 but questions about pathophysiology and variable expressivity still await answers.

Author contributions

M. Paucar, J. Waldthaler, and P. Svenningsson: study concept, data collection, and writing of the manuscript. P. Svenningsson: editing of the manuscript.

Study funding

This study was supported by the Stockholm County Council.

Disclosure

M. Paucar and J. Waldthaler have received research support from the Stockholm County Council. P. Svenningsson serves or has served on the scientific advisory board of CBD solutions AB; serves or has served on the editorial boards of PLoS One and Neuropharmacology; and has received research support from the Swedish Research Council, ALF Stockholm, and Wallenberg. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NG.

Acknowledgment

The authors are grateful to the patients for consenting to this report and to Dr. Ruth H. Walker for review of the draft.

Footnotes

  • Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NG.

  • The Article Processing Charge was funded by the authors.

  • Received March 23, 2018.
  • Accepted in final form June 6, 2018.
  • Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

  1. 1.↵
    1. Kirstein L,
    2. Silfverskiold BP
    . A family with emotionally precipitated drop seizures. Acta Psychiatr Neurol Scand 1958;33:471–476.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Shiang R,
    2. Ryan SG,
    3. Zhu YZ, et al
    . Mutations in the alpha 1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia. Nat Genet 1993;5:351–358.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Thomas RH,
    2. Chung SK,
    3. Wood SE, et al
    . Genotype-phenotype correlations in hyperekplexia: apnoeas, learning difficulties and speech delay. Brain 2013;136:3085–3095.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Bentivoglio AR,
    2. Loi M,
    3. Valente EM,
    4. Ialongo T,
    5. Tonali P,
    6. Albanese A
    . Phenotypic variability of DYT1-PTD: does the clinical spectrum include psychogenic dystonia? Mov Disord 2002;17:1058–1063.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Thomas RH,
    2. Drew CJG,
    3. Wood SE, et al
    . Ethnicity can predict GLRA1 genotypes in hyperekplexia. J Neurol Neurosurg Psychiatry 2015;86:341–343.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Chung SK,
    2. Vanbellinghen JF,
    3. Mullins JG, et al
    . Pathophysiological mechanisms of dominant and recessive GLRA1 mutations in hyperekplexia. J Neurosci 2010;30:9612–9620.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Harvey RJ,
    2. Topf M,
    3. Harvey K,
    4. Rees MI
    . The genetics of hyperekplexia: more than startle! Trends Genet 2008;24:439–447.
    OpenUrlCrossRefPubMed
View Abstract

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.ng.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Methods
    • Discussion
    • Author contributions
    • Study funding
    • Disclosure
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures

Related Articles

  • No related articles found.

Topics Discussed

  • All Genetics
  • All Movement Disorders
  • All Clinical Neurology

Alert Me

  • Alert me when eletters are published
Advertisement
Neurology Genetics: 7 (1)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Genetics | Online ISSN: 2376-7839

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise